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CaBACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after
myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most
commonly used agents, no randomized trial has compared their effects, and intervention data are lacking.
OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the
efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction.
METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was the
occurrence of refractory CS. Refractory CS was defined as CS with sustained hypotension, end-organ hypoperfusion and
hyperlactatemia, and high inotrope and vasopressor doses.
RESULTS Fifty-seven patients were randomized into 2 study arms, epinephrine and norepinephrine. For the primary
efficacy endpoint, cardiac index evolution was similar between the 2 groups (p ¼ 0.43) from baseline (H0) to H72. For the
main safety endpoint, the observed higher incidence of refractory shock in the epinephrine group (10 of 27 [37%] vs.
norepinephrine 2 of 30 [7%]; p ¼ 0.008) led to early termination of the study. Heart rate increased significantly with
epinephrine from H2 to H24 while remaining unchanged with norepinephrine (p < 0.0001). Several metabolic changes
were unfavorable to epinephrine compared with norepinephrine, including an increase in cardiac double product
(p ¼ 0.0002) and lactic acidosis from H2 to H24 (p < 0.0001).
CONCLUSIONS In patients with CS secondary to acute myocardial infarction, the use of epinephrine compared
with norepinephrine was associated with similar effects on arterial pressure and cardiac index and a higher incidence of
refractory shock. (Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
[OptimaCC]; NCT01367743) (JAmColl Cardiol 2018;72:173–82)©2018by theAmericanCollege of Cardiology Foundation.N 0735-1097/$36.00 https://doi.org/10.1016/j.jacc.2018.04.051
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ABBR EV I A T I ON S
AND ACRONYMS
AMI = acute myocardial
infarction
CS = cardiogenic shock
ECLS = extracorporeal life
support
ICU = intensive care unit
MAP = mean arterial pressure
PCI = percutaneous coronary
intervention
PCO2 = partial pressure of
carbon dioxide
RCT = randomized controlled
trial
SAP = systolic arterial pressure
SOFA = Sequential Organ
Failure Assessment
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174M ortality among patients withcardiogenic shock (CS) compli-cating acute myocardial infarc-
tion (AMI) remains high even in patients
undergoing early revascularization (1). Vaso-
pressor agents are administered in almost
90% of patients with CS with a positive class
II recommendation and Level of Evidence C
in U.S. and European guidelines (2,3). The
use of vasopressor agents during severe CS
is justified by the fact that for many patients,
the adequacy of end-organ blood flow is
roughly correlated with blood pressure,
with low blood pressures being associated
with an increased risk of mortality (4). How-
ever, these recommendations are mostly
based on experts’ opinion due to the lack of
randomized controlled trials (RCTs)
comparing the effects of vasopressor agents
in patients with CS (5–7). In a randomizedstudy comparing dopamine and norepinephrine (8),
a subgroup analysis of 280 patients with CS found
that dopamine was associated with increased 28-day
mortality compared with norepinephrine, leading
to a progressive decrease in dopamine use in this
indication (9).SEE PAGE 183Norepinephrine and epinephrine are currently the
most commonly used vasopressor agents in clinical
practice (4,9–12). Studies comparing epinephrine and
norepinephrine in patients with septic shock found
no significant differences in outcome (13). Neverthe-
less, these drugs may have certain specific effects in
patients with CS that could influence outcome.
Norepinephrine is likely less thermogenic than
epinephrine and therefore may have a more desirable
effect on myocardial oxygen consumption (14). Dur-
ing acute ischemic CS, norepinephrine induces
favorable effects on myocardial function (15,16).
Conversely, epinephrine may induce a higher cardiac
index and deliver available nutrients very rapidly to
the heart through lactate production (17). Twoas supported by a grant from INSERM-DHOS. Dr. Levy has receiv
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epinephrine may have deleterious effects associated
with greater circulating cardiovascular biomarkers in
patients with CS (10,18). Moreover, despite these po-
tential negative warnings, epinephrine is still used to
treat the most severe forms of CS after myocardial
infarction. However, none of these findings has been
assessed prospectively in this specific clinical setting.
The recent scientific statement from the American
Heart Association recommends performing RCTs to
identify the optimal vasopressor regimen in these
patients (19). In light of this information, the present
prospective, double-blind, multicenter RCT was
designed to compare both the hemodynamic efficacy
and tolerance of epinephrine and norepinephrine in
patients with CS secondary to percutaneous coronary
intervention (PCI)-treated AMI.
METHODS
STUDY DESIGN AND OVERSIGHT. The University
Hospital Center in Nancy (France) designed and
sponsored this multicenter, double-blind randomized
trial. Trial administration, data management, and
statistical analysis were performed by the sponsor.
The executive committee had unrestricted access to
the data, and the authors analyzed the data and pre-
pared the manuscript.
This multicenter RCT was conducted between
September 2011 and August 2016 in 9 French intensive
care units (ICUs). The trial was registered in June
2011 before inclusion of the first patient. The last
center was opened in June 2013. Secondary outcome
measures and the statistical analysis plan were upda-
ted on April 19, 2017, before freezing of the database
(April 24, 2017). The study received the approval of the
Nancy Hospital Institutional Review Board. Written
informed consent was obtained from the patients or
their closest relatives. The trial was overseen by an
independent data safety monitoring board.
STUDY POPULATION. Patients were eligible if they
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Excluded (n = 106)
Moribund: 34
Poor neurologic prognosis: 30
Immediate ECLS: 22
Declined to participate: 7
No medical insurance: 5
Other reasons: 8
Flow diagram of patient enrollment, showing exclusion at screening, randomization, and
follow-up. ECLS ¼ extracorporeal life support.
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175by using PCI; 2) systolic arterial pressure <90 mm Hg
or mean arterial pressure (MAP) <65 mm Hg without a
vasopressor agent or need for vasopressor therapy to
correct hypotension; 3) cardiac index <2.2 l/min/m2
in the absence of vasopressor or inotrope therapy;
4) pulmonary artery occlusion pressure >15 mm Hg or
echocardiographic evidence of high pressure;
5) echocardiographic ejection fraction <40% without
inotrope support (this criterion was not taken into
account in instances of treatment with dopamine,
norepinephrine, epinephrine, dobutamine, or milri-
none); 6) at least one evidence of tissue hypo-
perfusion (e.g., skin mottling, oliguria, elevated
lactate level, altered consciousness); and 7) an inser-
ted pulmonary artery catheter. In patients already
undergoing vasopressor therapy before randomiza-
tion, the study drug had to be introduced no more
than 6 h after the start of the open-label vasopressor
treatment.
Exclusion criteria were shock of other origin; im-
mediate indication for extracorporeal life support
(ECLS); patient age <18 years; cardiac arrest with early
signs of cerebral anoxia; septic, toxic, and obstructive
cardiomyopathy; patient without medical insurance;
adult patient under legal protection; and patients
considered moribund by the attending physician.
Moribund status was defined according to a state of
imminent death with no medical therapeutic option.
RANDOMIZATION AND BLINDING. Randomization
was computer generated, based on random blocks of
4, and stratified according to participating ICU.
Treatment assignments and patient reference number
were placed in sealed, opaque envelopes, which were
opened by an independent pharmacist in charge of
the preparation of the study drugs. Norepinephrine or
epinephrine syringes were prepared extemporane-
ously by the pharmacist. Each syringe was subse-
quently labeled with the patient’s number only and
was indistinguishable. Physicians, nurses, and the
local research staff were unaware of treatment
assignments.
STUDY TREATMENTS AND PROTOCOL. Vasopressor
doses are expressed in micrograms per kilogram per
minute. Doses were increased by 0.02 mg/kg/min (or
higher in emergency cases). The targeted MAP was
65 to 70 mm Hg (16). At inclusion (hour [H] 0), the
blind syringe was added to the open-label vaso-
pressor agent and as soon as MAP increased, the
nurses in charge decreased and subsequently dis-
continued administration of the open-label vaso-
pressor agent.
A patient was considered to be weaned from
vasopressor therapy after 24 h of hemodynamicstability without vasopressor support. During this
time lag, if MAP decreased to <65 to 70 mm Hg, the
study drug was reintroduced. Thereafter, an open-
label vasopressor agent was used if clinically neces-
sary. The study period lasted a maximum of 60 days.
In case of failure to reach a MAP of 65 to 70 mm Hg or
in case of arrhythmias refractory to therapy during
treatment with the study drug, the attending physi-
cian could switch to open-label vasopressor therapy.
All other treatment decisions were left to the discre-
tion of the attending physicians.
MEASURED VARIABLES. The following data were
recorded at H0 (randomization), H2, H4, H6, H12,
H24, H48, and H72: vital signs, systolic arterial
pressure (SAP), diastolic arterial pressure, MAP,
heart rate, right atrial pressure (RAP), systolic
pulmonary artery pressure, diastolic pulmonary
artery pressure, mean pulmonary artery pressure
(mPAP), pulmonary artery occlusion pressure,
mixed venous oxygen saturation (SVO2), cardiac
index, echocardiographic left ventricular ejection
fraction, arterial and mixed-venous blood gases,
arterial lactate, and doses of vasoactive agents
(cumulated and maximal). Biological variables,
microbiological data, and antibiotic therapy were
recorded daily for the first 7 days and thereafter on
days 14, 21, and 28.
Plasma samples were collected at H0, H24, H48,
and H72; they were stored at the study sites at –20C,
followed by storage at –80C at the central laboratory.
Growth differential factor 15, plasma high-sensitivity
troponin T levels, and N-terminal pro–B-type natri-
uretic peptide levels were measured.




(n ¼ 30) p Value
Age, yrs 68 (55–79) 66 (55–77) 0.63
Sex 0.047
Male 14 (52) 24 (80) NA
Female 13 (48) 6 (20) NA
Body mass index, kg/m2 25.2 (22.3–27.4) 25.4 (22.0–27.6) 0.98
Heart rate, beats/min 100 (70–118) 88 (75–110) 0.36
Systolic AP, mm Hg 109 (93-125) 98 (95–116) 0.29
Diastolic AP, mm Hg 54 (44–61) 57 (51–65) 0.14
Mean AP, mm Hg 72 (69–79) 71 (66–83) 0.62
Medical history
Hypertension 8 (30) 6 (20) 0.54
Diabetes 2 (7) 4 (13) 0.67
Stroke 2 (7) 2 (7) 0.99
Myocardial infarction 2 (7) 2 (7) 0.99
Resuscitation before inclusion 11 (41) 18 (60) 0.19
SAPS 2 score 59 (45–74) 54.5 (44–65) 0.46
SOFA score 10 (9–12) 9 (8–12) 0.32
Duration of shock before
randomization, h
6.1 (4.5–8.0) 6.0 (4.6–8.0) 0.71
Vasopressor treatment before inclusion NA NA 0.43
Epinephrine 8 (30) 5 (17) NA
Norepinephrine 19 (70) 24 (80) NA
None 0 (0) 1 (3) NA
ST-segment elevation 26 (96) 29 (97) 0.99
Arterial lactate, mmol/L 5.00 (2.70–6.06) 2.93 (1.94–4.82) 0.068
Mechanical ventilation 26 (96) 30 (100) 0.99
LVEF, % 34 (24–48) 34 (26–40) 0.65
Values are median (25th to 75th percentile) or n (%).
AP ¼ arterial pressure; LVEF ¼ left ventricular ejection fraction; NA ¼ not applicable; SAPS ¼ simplified acute
physiology score; SOFA ¼ Sequential Organ Failure Assessment.
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176CALCULATED VARIABLES. Cardiac index, oxygen
delivery index, oxygen consumption index, systemic
vascular resistance index, and stroke volume index
were calculated by using standard formulae. The
simplified acute physiology score 2 was calculated at
the time of admission to the ICU and at the time of
enrollment in the study; the Sequential Organ Failure
Assessment (SOFA) score was calculated daily for the
first 7 days and thereafter on days 14, 21, and 28.
OUTCOMES. Pr imary efficacy and safety
endpoints . The change in cardiac index was the
primary outcome variable. Cardiac index was
measured at randomization (H0) and at H2, H4, H6,
H12, H24, H48, and H72. The main safety endpoint
was the incidence of refractory CS. Refractory CS was
defined as CS with major cardiac dysfunction
assessed according to echocardiography, elevated
lactate level, and acute deterioration of organ
function (e.g., oliguria, liver failure) despite the use
of >1 mg/kg/min of epinephrine/norepinephrine or
dobutamine >10 mg/kg/min and/or intra-aortic
balloon support and sustained hypotension(SAP <90 mm Hg or MAP <65 mm Hg) despite
adequate intravascular volume. This event was
defined by the independent safety monitoring board
at the first meeting (September 2015) while
reviewing adverse events. The blind follow-up of
the serious adverse event declared by the
investigators to the pharmacovigilance team
revealed an expected global mortality but a high
incidence of refractory CS when considering the
entire population. Because refractory CS was not an
expected serious adverse event of both drugs, this
event was not specifically followed. After having
unblinding the cases, the data and safety
monitoring board found an imbalance between the 2
groups for refractory CS incidence as declared by
the investigators. Therefore, the pharmacovigilance
team of the trial provided advice for the systematic
reporting of this serious adverse event as a serious
adverse event of interest and asked the main
investigator to perform a review of these cases. This
new safety event was reported to the ANSM (French
Agency for Drugs Safety), which terminated the
study in April 2016. At the end of the study but
before freezing the database, all case report forms
were reviewed by 2 physicians not participating in
the study to both confirm the diagnosis of refractory
shock and to search for other potential cases that
were not declared.
Secondary efficacy and safety outcomes. Secondary effi-
cacy endpoints were changes in other hemodynamic
variables over time, cardiac power index (20), use of
inotropes, lactate level and lactate clearance (21),
biomarker levels, and SOFA score evolution during
the first 72 h. Regarding safety, specifically screened
adverse events comprised arrhythmias (i.e., ventric-
ular tachycardia, ventricular fibrillation, atrial
fibrillation).
STATISTICAL ANALYSIS. The analysis used an
intention-to-treat strategy; patients were analyzed
according to their randomization arm. The primary
efficacy endpoint was the cardiac index. To detect a
difference of at least 0.64 SDs between the 2 groups, a
sample size of 40 patients per group was required to
achieve 80% power with a 2-tailed significance level
of 5%. Thus, according to the baseline cardiac index
of SHOCK (Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock?) trial
patients (22), for an initial average cardiac index of 1.8
 0.6 l/min/m2, a statistically significant result cor-
responded to a difference of 0.38 l/min/m2.
All analyses were performed by using R statistical
software (R Foundation for Statistical Computing,
Vienna, Austria). The 2-tailed significance level was
set at p < 0.05. Continuous variables are described as
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(A) Mean arterial pressure; (B) cardiac index; (C) heart rate; (D) stroke volume index; and (E) refractory cardiogenic shock distribution.
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Refractory shock 10 (37) 2 (7) 0.008 8.24 (1.61–42.18) 0.011
Arrhythmia 11 (41) 10 (33) 0.59 1.37 (0.47–4.05) 0.56
ECLS 3 (11) 1 (3) 0.34 3.62 (0.35–37.14) 0.28
Death 14 (52) 11 (37) 0.29 1.86 (0.65–5.36) 0.25
Death within 7 days 8 (30) 3 (10) 0.093 3.79 (0.89–16.17) 0.072
Death within 28 days 13 (48) 8 (27) 0.11 2.55 (0.84–7.72) 0.097
Values are n (%) unless otherwise indicated. Odds ratios were expressed by using the norepinephrine group as
reference. *p value from the Fisher exact test. †p value from the Wald test.
ECLS ¼ extracorporeal life support.
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178median (interquartile range) and categorical variables
as frequencies (percentages). Comparison of baseline
characteristics according to treatment group was
conducted by using the nonparametric Wilcoxon test
for continuous variables and the Fisher exact test for
categorical variables. Associations between treatment
group and adverse events were assessed by using
logistic regression model. Odds ratios are presented
with their 95% confidence intervals using the
norepinephrine group as reference. Survival rates for
the composite outcome of “death and/or ECLS
implementation within 7 days” according to treat-
ment group are illustrated by using Kaplan-Meier
analyses. Differences between survival curves were
analyzed by using the log-rank test.
The evolution of outcomes (MAP, cardiac index,
heart rate, stroke volume index, arterial lactate,
cardiac double product, cardiac power index, and
SvO2) during the hemodynamic assessment period
(72 h) was compared in the 2 groups by using
repeated-measures analysis of variance based on
the ranks of the values with the rank of baseline
value as adjustment covariate. Because the post-
baseline values were constrained by the clinical
events observed during the follow-up (death or
ECLS implantation), each value was ranked from
lowest to highest at each time point, with the worst
rank attributed for deceased patients at each time
point after their death and the second worst rank
for patients who underwent ECLS at each time
point after their implantation (additional details are
provided in the Online Appendix). The evolution of
other parameters was compared in the 2 groups by
using repeated measures analysis of variance with
baseline value as the adjustment covariate. It
should be noted that certain outcomes were not
specified a priori as primary/secondary efficacy or
safety endpoints. Therefore, analysis of these out-
comes must be considered as a post hoc analysis.RESULTS
STUDY POPULATION. Among 163 screened patients,
106 were excluded predominantly for moribund sta-
tus (n ¼ 34), cardiac arrest with early signs of cerebral
anoxia (n ¼ 30), and early ECLS requirement (n ¼ 22)
(Figure 1). A total of 57 patients were ultimately
included, 27 in the epinephrine group and 30 in the
norepinephrine group. Patient characteristics at in-
clusion are provided in Table 1 and Online Table 1.
With the exception of sex, there was no difference
between the 2 groups. Eleven patients (41%) in the
epinephrine group and 18 patients (60%) in the
norepinephrine group were successfully resuscitated
after a cardiac arrest before enrollment in the study
(p ¼ 0.19). At inclusion, 56 (98%) of 57 patients were
mechanically ventilated. Coronary and PCI charac-
teristics are described in Online Table 2.
In all studied patients, urgent PCI revasculariza-
tion was successfully performed with a resulting
Thrombolysis In Myocardial Infarction flow grade
score of 3 at the end of the procedure. The open-label
vasopressor regimen before randomization did not
differ between groups. An intra-aortic balloon pump
was inserted after PCI in 16 (59%) of 27 patients in the
epinephrine group and in 15 (50%) of 30 patients in
the norepinephrine group (p ¼ 0.60). No mechanical
complication of AMI was encountered.
PRIMARY EFFICACY AND SAFETY OUTCOME. For
the main efficacy endpoint, using an intention-to-
treat analysis strategy and taking into account pa-
tients who died or underwent ECLS implantation as
worst outcomes (as detailed in the Methods section),
cardiac index evolution did not significantly differ
between the epinephrine and norepinephrine groups
(p ¼ 0.43) (Central Illustration). Cardiac index was
transiently higher in the epinephrine group at H2
(p ¼ 0.011) and H4 (p ¼ 0.036) (Online Table 3).
For the main safety endpoint, epinephrine was
associated with a higher incidence of refractory CS (10
of 27 [37%] vs. 2 of 30 [7%]; p ¼ 0.011) (Central
Illustration, Table 2). Given the higher incidence of
refractory shock in the epinephrine group, the data
and safety monitoring board terminated the study
prematurely. Importantly, this adverse event was not
planned as the primary safety outcome at trial initi-
ation. It was, however, systematically recorded as an
outcome of interest and carefully reviewed after the
vigilance team of the trial identified an unexpected
high rate of this outcome during the first year of the
study. As a consequence, although this event was not
defined before trial initiation, it was nonetheless
defined during the course of the trial.






















































































































(A) Arterial lactate; (B) cardiac double product; (C) cardiac power index; and (D) mixed venous oxygen saturation (SvO2). All parameters and variables were compared
between the 2 groups at baseline (hour [H] 0) and at H2, H4, H6, H12, H24, H48, and H72 with analysis of variance adjusted on baseline measurement. Data are
presented as median (interquartile ranges). The p values were calculated by using repeated measures analysis of variance. *p < 0.05.
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179SECONDARY HEMODYNAMIC AND METABOLIC
EFFICACY ENDPOINTS. Regarding the study drugs,
the dose needed to obtain a MAP of 70 mm Hg was 0.7
 0.5 mg/kg/min in the epinephrine group and 0.6 
0.7 mg/kg/min in the norepinephrine group (p ¼ 0.66).
There was no statistically significant difference with
regard to duration (p ¼ 0.15), the dose at different
time points (from H0 to H72; p ¼ 0.66), and the
maximal dose (p ¼ 0.79) of study drugs in the 2
groups (Online Table 4). The evolution of SAP(p ¼ 0.11), diastolic arterial pressure (p ¼ 0.13), and
MAP (p ¼ 0.80) during the first 3 days of the study was
similar between groups (Online Table 5).
Mean heart rate increased significantly in the
epinephrine group, whereas it did not change signif-
icantly in the norepinephrine group (p ¼ 0.031)
(Central Illustration, Online Table 3). The evolution of
stroke volume index (p ¼ 0.25) and cardiac power
index (p ¼ 0.064) was similar between groups
(Figure 2). Cardiac double product, a surrogate of
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180myocardial oxygen consumption, increased in the
epinephrine group, whereas it did not change in the
norepinephrine group. The venous-arterial partial
pressure of carbon dioxide (PCO2) gradient was
similar between the epinephrine and norepinephrine
groups (p ¼ 0.59) (Online Table 5). The mean systemic
vascular resistance index progressively decreased
with no significant differences (p ¼ 0.44). Mean pul-
monary artery pressure (p ¼ 0.48) and pulmonary
artery occlusion pressure (p ¼ 0.38) evolved similarly
between the 2 groups. Finally, left ventricular ejec-
tion fraction progressively increased in a similar
manner between both groups (p ¼ 0.87).
Regarding the combined use of inotropes,
dobutamine was used in 18 (67%) of 27 patients in
the epinephrine group and in 20 (67%) of 30 pa-
tients in the norepinephrine group (p ¼ 0.99).
Mean dobutamine treatment duration was 22 (7 to
72) h in the epinephrine group and 90 (63 to 161) h
in the norepinephrine group (p ¼ 0.0009). There
was no statistically significant difference in dobut-
amine at the different time points (from H0 to H72;
p ¼ 0.78) or in the maximal dose (p ¼ 0.88)
(Online Table 4).
Regarding metabolic changes, during the first 24 h,
epinephrine use was associated with metabolic
acidosis (p ¼ 0.0004) and increased lactate level (p <
0.0001) (Figure 2), whereas arterial pH increased and
lactate level decreased in the norepinephrine group.
Lactate clearance was observed much earlier and
occurred at a faster pace in the norepinephrine group
(p < 0.0001). The evolution of SVO2 (p ¼ 0.20) (Online
Table 3), oxygen consumption index (p ¼ 0.67) and
oxygen delivery index (p ¼ 0.69) during the study
period was similar between the 2 groups (Online
Table 5).
Regarding organ dysfunction, the SOFA score and
its components did not differ between the 2 groups,
either at inclusion or during patient course (p ¼ 0.44).
There were no differences in variations during the
study period with regard to creatinine, urea, diuresis,
aspartate transaminase, and bilirubin levels between
the 2 groups (Online Table 6). The decrease in alanine
transaminase level occurred faster in the norepi-
nephrine group (p ¼ 0.011). Renal replacement ther-
apy was used in 7 (26%) of 27 patients in the
epinephrine group and in 2 (7%) of 30 patients in the
norepinephrine group (p ¼ 0.07). No statistically sig-
nificant difference was observed in levels of the car-
diac biomarkers N-terminal pro–B-type natriuretic
peptide (p ¼ 0.20) and cardiac troponin T (p ¼ 0.21)
during the first 72 h. By contrast, levels of the car-
diovascular prognostic marker growth differential
factor 15 were markedly higher in the epinephrineversus norepinephrine group from H24 to H72
(p ¼ 0.002) (Online Figure 1).
The incidence of arrhythmia was not significantly
different between the epinephrine and norepineph-
rine groups (11 of 27 [41%] vs. 10 of 30 [33%];
p ¼ 0.56). Two patients from the epinephrine group
were switched to open-label norepinephrine due to
sustained ventricular tachycardia.
MORTALITY. Death at 60 days occurred in 14 (52%) of
27 patients in the epinephrine group and in 11 (37%) of
30 patients in the norepinephrine group (p ¼ 0.25)
(Table 2). Epinephrine use was associated with a trend
toward an increased risk of death on day 7 (p ¼ 0.08)
and with a significantly higher risk of death or ECLS
requirement on day 7 (p ¼ 0.031) (Online Figure 2).
There was also a trend for an increased risk of death
or ECLS requirement on day 28 (p ¼ 0.064). Post hoc
results including ECLS implantation are further
described in Online Table 7.
DISCUSSION
This trial is the first randomized study to compare
epinephrine and norepinephrine in patients with CS
complicating AMI. The main result of the present
study is that epinephrine use was associated with
very transient improvement in cardiac index but with
marked safety concerns, including refractory shock.
Compared with norepinephrine, epinephrine admin-
istration was also associated with an increase in heart
rate, prolonged acidosis, and lactatemia. Other he-
modynamic variables did not differ significantly be-
tween treatment groups.
COMPARISON BETWEEN NOREPINEPHRINE AND
EPINEPHRINE IN CARDIOGENIC SHOCK. The com-
parison of the 2 groups was conducted by using a
statistical method that allowed inclusion of the data
of the patients who died or underwent ECLS im-
plantation. Briefly, because comparisons were based
on ranks, death or ECLS implantation was consid-
ered as having a worst rank than largely abnormal
values of continuous data in the absence of these
events. This strategy maintained the intention-to-
treat nature of the analysis. Both drugs were effi-
cient in increasing MAP. As previously described
(23), MAP was always higher than the target MAP
with no differences between the 2 groups.
Epinephrine was associated with a marked and
sustained increase in heart rate compared with
norepinephrine-treated patients. This outcome was
likely due to the high number of beta2-adreno-
ceptors present in the atria (approximately 30% of
the total beta-adrenoceptors) (24,25).
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In patients with AMI complicated by CS who have un-
dergone successful primary angioplasty, shock is less refractory
when arterial pressure is supported with norepinephrine rather
than with epinephrine.
TRANSLATIONAL OUTLOOK: Future studies should compare
the myocardial energetic effects of various catecholamines and
their impact on clinical outcomes in patients with CS in clinical
settings other than AMI.
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181The tachycardia observed in the epinephrine group
led to a transient increase in cardiac index from H0 to
H4, whereas stroke index was similar in both groups.
Importantly, epinephrine-treated patients exhibited
substantial lactic acidosis, an increased cardiac dou-
ble product (which can be considered as a surrogate of
myocardial oxygen consumption) (26), and similar
perfusion markers such as SVO2 and arteriovenous
PCO2. Thus, it is highly likely that all of these effects
were linked to receptor affinity differences because
only epinephrine acts on beta2-receptors (27). Exper-
imentally, the main difference between the 2 drugs is
that epinephrine increases the contractile force of
myocardial fibers to a lesser degree than norepi-
nephrine at the expense of a higher energy cost
leading to lower cardiac efficiency (28). Moreover,
when used at higher doses, epinephrine is associated
with negative inotropic effects. We and others have
shown that epinephrine-induced lactic acidosis is a
cost-energy mechanism mainly related to the activa-
tion of the sarcolemmal sodium-potassium adenosine
triphosphatase pump through beta2-receptors and
cAMP (cyclic adenosine monophosphate) production
in an adenosine triphosphate–consuming process
(29,30).
EPINEPHRINE USE AND REFRACTORY CARDIOGENIC
SHOCK. Despite premature termination of the trial
and the relatively small treatment groups, we were
able to identify a clinically meaningful difference in
the number with refractory CS with epinephrine use
compared with norepinephrine. The main aim of
resuscitation during CS is to improve global perfu-
sion and not to obtain a predefined cardiac index.
Monitoring tissue perfusion can be achieved by us-
ing arterial lactate, venoarterial gradients in PCO2,
and central venous or mixed venous oxygen satu-
ration (3,31). Thus, to obtain the same effect on
global perfusion and tissue oxygenation,
epinephrine-treated patients had higher cardiac
double product, lactic acidosis, and a differential
regulation of growth differential factor 15 pathway
(a stress responsive cytokine that increases in
response to hypoxia, oxidative stress, inflammation,
and cell injury) (32). Overall, these effects could
explain the increased occurrence of refractory CS in
epinephrine-treated patients secondary to excessive
adrenergic overstimulation likely mimicking an
acute catecholamine-induced cardiomyopathy as
previously described with epinephrine use (33) or
upon administration of very high doses of dobut-
amine (34).
STUDY LIMITATIONS. The main limitation is that our
study lasted 4 years and included only 57 patientsduring this period. Two reasons may explain this low
inclusion rate. First, at the time of the study, the
concept of a cardiac center and heart team was not
developed in France. Therefore, in the same hospital,
a patient with CS secondary to myocardial infarction
might have been treated in a different ICU, leading to
a relatively low incidence of this pathology in 1 spe-
cific ICU. Second, the mandatory use of a pulmonary
artery catheter at the time, which is currently rarely
used in France for shock monitoring, markedly
limited the number of potential centers involved in
the study. Nevertheless, our studied population was
similar to studies assessing the most severe pre-
sentations of CS related to AMI both for clinical
characteristics and mortality (1,19,35,36). Finally, the
increase in cardiac index and heart rate associated
with lactic acidosis has been described with
epinephrine use in both septic (37), hemorrhagic, and
cardiogenic (38) shock. Nevertheless, because CS en-
compasses a wide spectrum of hemodynamic states
(19), the potential deleterious effects associated
with its use such as refractory CS may differ in CS
due to other etiologies (e.g., poisoning, post-
cardiopulmonary bypass, myocarditis).
CONCLUSIONS
In patients with CS secondary to acute MI, the use of
epinephrine compared with norepinephrine was
associated with similar effects on arterial pressure
and cardiac index and a higher incidence of refractory
shock.
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